Skip to content

Investigation on drug resistance and gene polymorphism of Helicobacter pylori

Investigation on drug resistance and gene polymorphism of Helicobacter pylori

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041393
Enrollment
Unknown
Registered
2020-12-24
Start date
2017-01-02
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Helicobacter pylori infection group:Nil

Sponsors

Kuichong People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18–70 years; (2) had not been previously treated for H.pylori; (3) had not received PPI, H2 receptor antagonist, expectorant or antibiotic treatment in the past 4weeks; (4) had not previously received gastric surgery; and (5) had neither heart, lung, liver and kidney disorders nor any digestive system malignancies.

Exclusion criteria

Exclusion criteria: The exclusion criteria were having had previous treatment for H.pylori infection, or having taken a proton pump inhibitor, H2 receptor antagonist, expectorant, or antibiotic treatment within the last four weeks prior to endoscopy, past history of gastric surgery, or having been diagnosed with gastrointestinal cancer, severe heart, lung, liver, kidney or blood system disorders.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori infection;The drug resistance rates of helicobacter pylori;

Countries

China

Contacts

Public ContactShuzhen Zhang

Kuichong People's Hospital

zhangsz0618@163.com+86 13691689639

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026